Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 16 August 2012 | By Louise Zornoza,
China's State Food and Drug Administration (SFDA) issued new regulations on 15 August instructing provincial governments to publish on their websites so-called Black Lists of drug and device companies that engage in counterfeiting and related illegal activities.
The websites are to include the name of the company, its business address, the name of the legal representative or responsible person, and the individual's title. Violations that would justify adding a company to a Black List include: production and sale of counterfeit drugs, manufacture of devices without having obtained a license, entering false information on registration certificates, and fraud and bribery.
The guidance comes just two months after the black lists were first proposed by SFDA.
Read more:
Read all Breaking News from RegLink
Tags: Black List, Counterfeit, SFDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.